Inhibition of ADP ribosylation prevents and cures Helicobacter-induced gastric preneoplasia

Cancer Research

Volumn 70, Issue 14, 2010, Pages 5912-5922

  Toller, Isabella M ^a   Altmeyer, Matthias ^a   Kohler, Esther ^a   Hottiger, Michael O ^a   Müller, Anne ^a  

^a UNIVERSITY OF ZURICH   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

BISMUTH CITRATE; CD28 ANTIGEN; CD3 ANTIGEN; GAMMA INTERFERON; INTERLEUKIN 2; INTERLEUKIN 2 RECEPTOR ALPHA; IONOMYCIN; METRONIDAZOLE; N (5,6 DIHYDRO 6 OXO 2 PHENANTHRIDINYL) 2 DIMETHYLAMINOACETAMIDE; PHORBOL MYRISTATE; TETRACYCLINE;

ADENOSINE DIPHOSPHATE RIBOSYLATION; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; ATROPHIC GASTRITIS; CELL FUNCTION; CHEMOPROPHYLAXIS; CONTROLLED STUDY; CYTOKINE PRODUCTION; EFFECTOR CELL; EPITHELIUM HYPERPLASIA; ERADICATION THERAPY; GENETIC TRANSCRIPTION; HELICOBACTER FELIS; HELICOBACTER PYLORI; INTESTINE METAPLASIA; LYMPHOCYTIC INFILTRATION; MALE; MESENTERY LYMPH NODE; MOUSE; NONHUMAN; POLARIZATION; PRIORITY JOURNAL; STOMACH MUCOSA; T LYMPHOCYTE; T LYMPHOCYTE ACTIVATION; TH1 CELL;

ADENOSINE DIPHOSPHATE; ANIMALS; GASTRITIS, ATROPHIC; HELICOBACTER INFECTIONS; HELICOBACTER PYLORI; INTERFERON-GAMMA; INTERLEUKIN-2; LYMPHOCYTE ACTIVATION; MALE; MICE; MICE, INBRED C57BL; MICE, TRANSGENIC; PHENANTHRENES; POLY(ADP-RIBOSE) POLYMERASES; PRECANCEROUS CONDITIONS; STOMACH NEOPLASMS; T-LYMPHOCYTES;

EID: 77955045071     PISSN: 00085472     EISSN: 15387445     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-10-0528     Document Type: Article

References (35)

1. Mantovani A, Allavena P, Sica A, Balkwill F. Cancer-related inflammation. Nature 2008;454:436-44.
2. Huang JQ, Zheng GF, Sumanac K, Irvine EJ, Hunt RH. Meta-analysis of the relationship between cagA seropositivity and gastric cancer. Gastroenterology 2003;125:1636-44.
3. Parsonnet J, Friedman GD, Orentreich N, Vogelman H. Risk for gastric cancer in people with CagA positive or CagA negative Helicobacter pylori infection. Gut 1997;40:297-301.
4. Parsonnet J, Friedman GD, Vandersteen DP, et al. Helicobacter pylori infection and the risk of gastric carcinoma. N Engl J Med 1991;325:1127-31.
5. Peek RM, Jr., Blaser MJ. Helicobacter pylori and gastrointestinal tract adenocarcinomas. Nat Rev Cancer 2002;2:28-37.
6. Correa P. Helicobacter pylori and gastric carcinogenesis. Am J Surg Pathol 1995;19 Suppl 1:S37-43.
7. Fox JG, Wang TC. Inflammation, atrophy, and gastric cancer. J Clin Invest 2007;117:60-9.
8. Sayi A, Kohler E, Hitzler I, et al. The CD4+ T cell-mediated IFN-γ response to Helicobacter infection is essential for clearance and determines gastric cancer risk. J Immunol 2009;182:7085-101.
9. Toller IM, Hitzler I, Sayi A, Mueller A. Prostaglandin E2 prevents Helicobacter-induced gastric preneoplasia and facilitates persistent infection in a mouse model. Gastroenterology 2009;138:1455-67.
10. Altmeyer M, Messner S, Hassa PO, Fey M, Hottiger MO. Molecular mechanism of poly(ADP-ribosyl)ation by PARP1 and identification of lysine residues as ADP-ribose acceptor sites. Nucleic Acids Res 2009;37:3723-38.
11. Kickhoefer VA, Siva AC, Kedersha NL, et al. The 193-kD vault protein, VPARP, is a novel poly(ADP-ribose) polymerase. J Cell Biol 1999;146:917-28.
12. Smith S, Giriat I, Schmitt A, de Lange T. Tankyrase, a poly(ADPribose) polymerase at human telomeres. Science 1998;282:1484-7.
13. Jijon HB, Churchill T, Malfair D, et al. Inhibition of poly(ADP-ribose) polymerase attenuates inflammation in a model of chronic colitis. Am J Physiol Gastrointest Liver Physiol 2000;279:G641-51.
14. Oumouna M, Datta R, Oumouna-Benachour K, et al. Poly(ADP-ribose) polymerase-1 inhibition prevents eosinophil recruitment by modulating Th2 cytokines in a murine model of allergic airway inflammation: a potential specific effect on IL-5. J Immunol 2006;177:6489-96.
15. Veres B, Gallyas F, Jr., Varbiro G, et al. Decrease of the inflammatory response and induction of the Akt/protein kinase B pathway by poly-(ADP-ribose) polymerase 1 inhibitor in endotoxin-induced septic shock. Biochem Pharmacol 2003;65:1373-82.
16. Bryant HE, Schultz N, Thomas HD, et al. Specific killing of BRCA2-deficient tumours with inhibitors of poly(ADP-ribose) polymerase. Nature 2005;434:913-7.
17. Farmer H, McCabe N, Lord CJ, et al. Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy. Nature 2005;434:917-21.
18. Audeh MW, Penson RT, Friedlander M, et al. Phase II trial of the oral PARP inhibitor olaparib (AZD2281) in BRCA-deficient advanced ovarian cancer. J Clin Oncol 2009;27:5500.
19. Drew Y, Plummer R. PARP inhibitors in cancer therapy: two modes of attack on the cancer cell widening the clinical applications. Drug Resist Updat 2009;12:153-6.
20. Fong PC, Boss DS, Yap TA, et al. Inhibition of poly(ADP-ribose) polymerase in tumors from BRCA mutation carriers. N Engl J Med 2009;361:123-34.
21. Tutt A, Robson M, Garber J, et al. Phase II trial of the oral PARP inhibitor olaparib in BRCAdeficient advanced breast cancer. J Clin Oncol 2009;27:CRA501.
22. Soriano FG, Pacher P, Mabley J, Liaudet L, Szabo C. Rapid reversal of the diabetic endothelial dysfunction by pharmacological inhibition of poly(ADP-ribose) polymerase. Circ Res 2001;89:684-91.
23. Wang ZQ, Auer B, Stingl L, et al. Mice lacking ADPRT and poly (ADP-ribosyl)ation develop normally but are susceptible to skin disease. Genes Dev 1995;9:509-20.
24. Lee A, Fox JG, Otto G, Murphy J. A small animal model of human Helicobacter pylori active chronic gastritis. Gastroenterology 1990;99:1315-23.
25. Fox JG, Beck P, Dangler CA, et al. Concurrent enteric helminth infection modulates inflammation and gastric immune responses and reduces helicobacter-induced gastric atrophy. Nat Med 2000;6:536-42.
26. Lee A, Chen M, Coltro N, et al. Long term infection of the gastric mucosa with Helicobacter species does induce atrophic gastritis in an animal model of Helicobacter pylori infection. Zentralbl Bakteriol 1993;280:38-50.
27. Tan MP, Pedersen J, Zhan Y, et al. CD8+ T cells are associated with severe gastritis in Helicobacter pylori-infected mice in the absence of CD4+ T cells. Infect Immun 2008;76:1289-97.
28. Lee CW, Rickman B, Rogers AB, Ge Z, Wang TC, Fox JG. Helicobacter pylori eradication prevents progression of gastric cancer in hypergastrinemic INS-GAS mice. Cancer Res 2008;68:3540-8.
29. Rokkas T, Pistiolas D, Sechopoulos P, Robotis I, Margantinis G. The long-term impact of Helicobacter pylori eradication on gastric histology: a systematic review and meta-analysis. Helicobacter 2007;12 Suppl 2:32-8.
30. Sharpe AH, Abbas AK. T-cell costimulation-biology, therapeutic potential, and challenges. N Engl J Med 2006;355:973-5.
31. Smith KA. Interleukin-2: inception, impact, and implications. Science 1988;240:1169-76.
32. Cuzzocrea S. Shock, inflammation and PARP. Pharmacol Res 2005;52:72-82.
33. Di Paola R, Mazzon E, Xu W, et al. Treatment with PARP-1 inhibitors, GPI 15427 or GPI 16539, ameliorates intestinal damage in rat models of colitis and shock. Eur J Pharmacol 2005;527:163-71.
34. Mazzon E, Dugo L, Li JH, et al. GPI 6150, a PARP inhibitor, reduces the colon injury caused by dinitrobenzene sulfonic acid in the rat. Biochem Pharmacol 2002;64:327-37.
35. Sanchez-Fidalgo S, Villegas I, Martin A, Sanchez-Hidalgo M, Alarcon de la Lastra C. PARP inhibition reduces acute colonic inflammation in rats. Eur J Pharmacol 2007;563:216-23.